Search Results
Sep 02, 2026, 10:30 ET Biosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™
Piramal Pharma Ltd. (PPL) completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited, enabling PPL to expand its presence in the biologics sector. With the finalization of this deal, PPL will fully embed the subsidiary's advanced large molecule
More news about: MarketsandMarkets
Aug 27, 2026, 08:31 ET Piramal Pharma refuerza las operaciones preparadas para el futuro con una reducción del 22,6 % de las emisiones, un 41 % de energías renovables y cero observaciones de OAI de la FDA de EE. UU.
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Acerca de Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), ofrece una cartera
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:51 ET Piramal Pharma rafforza le proprie attività operative rendendole a prova di futuro, grazie a una riduzione del 22,6% delle emissioni, al 41% di energia rinnovabile e a zero osservazioni classificate come OAI (Official Action Indicated) da parte della USFDA
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Profilo di Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offre un portafoglio
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:43 ET Piramal Pharma renforce ses opérations prêtes pour l'avenir avec une réduction de 22,6 % des émissions, 41 % des énergies renouvelables et « zéro observation » de l'OAI par la FDA américaine
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf À propos de Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offre un portefeuille
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:36 ET Piramal Pharma、排出量22.6%削減、再生可能エネルギー比率41%、USFDAのOAI指摘ゼロで将来に備えた事業運営を強化
Committee）の監督下に置かれ、ESGへの配慮が長期的な事業パフォーマンスおよび価値創出に不可欠な要素であり続けるよう徹底しています。サステナビリティレポートはGRIスタンダードに準拠し、SASBおよびUNGCの枠組みに沿って作成されており、持続可能な成長、責任ある資本配分、実効性のあるステークホルダーエンゲージメントに対するPPLのコミットメントを明確に示しています。詳細については、以下で公開されている完全版レポートをご参照ください：https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Piramal
More news about: Piramal Pharma Limited
Aug 27, 2026, 07:21 ET Piramal Pharma stärkt zukunftsfähige Betriebsabläufe durch Emissionsreduktion von 22,6 %, Anteil erneuerbarer Energien von 41 % und null Beanstandungen im Rahmen des OAI-Verfahrens der US-Lebensmittelüberwachungs- und Arzneimittelbehörde (USFDA)
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf Über Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635) bietet ein Portfolio
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:49 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio
More news about: Piramal Pharma Limited
Aug 26, 2026, 10:45 ET Piramal Pharma Strengthens Future Ready Operations with 22.6% Emissions Reduction, 41% Renewable Energy and Zero USFDA OAI Observations
https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/PPL-Sustainability-Report-2025-26.pdf About Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio
More news about: Piramal Pharma Limited
Aug 21, 2026, 07:05 ET PPL to Pay Quarterly Stock Dividend Oct. 1, 2026
About PPLPPL Corporation (NYSE: PPL), headquartered in Allentown, Pennsylvania, is a leading U.S. energy company focused on providing electricity and natural gas safely,
More news about: PPL Services Corporation
Aug 19, 2026, 18:00 ET Piramal Pharma Limited schließt die Übernahme einer Mehrheitsbeteiligung an Yapan Bio Private Limited ab
Infolge dieser Transaktion hält PPL nun 74 % des Eigenkapitals von Yapan Bio, womit Yapan Bio zu einer Tochtergesellschaft von PPL geworden ist.Die am 18. August 2026 abgeschlossene Übernahme stellt einen wichtigen Schritt im Rahmen des langfristigen Plans von PPL dar, seine Präsenz im Bereich der
More news about: Piramal Pharma Solutions
Aug 19, 2026, 14:56 ET Piramal Pharma Limited completa l'acquisizione di una quota di controllo di Yapan Bio Private Limited
milioni di USD. A seguito di questa transazione, PPL possiede ora il 74% del capitale di Yapan Bio, rendendo Yapan Bio una sua filiale.Perfezionata il 18 agosto 2026, l'acquisizione segna un importante passo avanti nel piano a lungo termine di PPL per espandere la sua presenza nel settore dei farmaci
More news about: Piramal Pharma Solutions
Aug 19, 2026, 11:21 ET Piramal Pharma Limited finalise l'acquisition d'une participation majoritaire dans Yapan Bio Private Limited
un montant total en numéraire de 76 crore INR, soit 7,95 millions USD. À la suite de cette opération, PPL détient désormais 74 % du capital de Yapan Bio, ce qui fait de Yapan Bio une filiale de PPL.
More news about: Piramal Pharma Solutions
Aug 19, 2026, 06:36 ET Piramal Pharma Limited completa la adquisición de una participación mayoritaria en Yapan Bio Private Limited
rupias INR, el equivalente a 7,95 millones de dólares estadounidenses. Como resultado de esta transacción, PPL ya cuenta con el 74% del capital social de Yapan Bio, convirtiéndola en una filial de PPL.
More news about: Piramal Pharma Solutions
Aug 19, 2026, 03:50 ET Piramal Pharma Limited、Yapan Bio Private Limitedの支配持ち分の取得を完了
インド・ムンバイ, 2026年8月19日 /PRNewswire/ -- Piramal Pharma Ltd. （NSE：PPLPHARMA）（BSE：543635) （「PPL」）は、ハイデラバードに拠点を置き、ワクチンおよびバイオ医薬品を専門とするCDMOであるYapan Bio Private Limited（「Yapan Bio」）の株式の40.67％を追加取得しました。買収総額は現金₹76cr INR （795万米ドル）です。本取引の結果、PPLは現在、Yapan Bioの株式の74% を保有しており、Yapan
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:44 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now
More news about: Piramal Pharma Solutions
Aug 18, 2026, 15:36 ET Piramal Pharma Limited Completes Acquisition of Controlling Stake in Yapan Bio Private Limited
543635) ("PPL) has completed the acquisition of an incremental 40.67% stake in Yapan Bio Private Limited ("Yapan Bio"), a Hyderabad-based CDMO specializing in vaccines and biologics for an aggregate cash consideration of ₹76 crore INR, or $7.95M USD. As a result of this transaction, PPL now
More news about: Piramal Pharma Solutions
Aug 07, 2026, 07:33 ET PPL Corporation Delivers Solid Second-Quarter 2026 Earnings; Reaffirms Guidance and Long‑Term Growth Outlook
guidance.See the table at the end of this news release for a complete reconciliation of the earnings forecast.About PPLPPL Corporation (NYSE: PPL), headquartered in Allentown, Pennsylvania, is a leading U.S. energy company focused on providing electricity and natural gas safely, reliably
More news about: PPL Services Corporation
Aug 05, 2026, 04:24 ET Piramal Pharma Solutions amplia il proprio stabilimento per API peptidici con una suite avanzata di essiccazione a spruzzo
wellness. Inoltre, una delle aziende associate di PPL, Abbvie Therapeutics India Private Limited, una joint venture tra Abbvie e PPL, è emersa come uno dei leader di mercato nell'area della terapia oftalmologica nel mercato farmaceutico indiano. Inoltre, PPL detiene una partecipazione strategica di minoranza
More news about: Piramal Pharma Solutions
Aug 05, 2026, 02:06 ET Piramal Pharma Solutions erweitert Peptid-API-Anlage um moderne Sprühtrocknungsanlage
Therapeutics India Private Limited, eines der assoziierten Unternehmen von PPL und ein Gemeinschaftsunternehmen von Abbvie und PPL, als einer der Marktführer im Bereich der Augenheilkunde auf dem indischen Pharmamarkt etabliert. Außerdem hält PPL eine strategische Minderheitsbeteiligung an Yapan Bio Private Limited,
More news about: Piramal Pharma Solutions
Aug 04, 2026, 23:05 ET Piramal Pharma Solutions agrandit son site de production d'API peptidiques avec l'ajout d'une unité de séchage par atomisation de pointe
XÀ propos de Piramal Pharma LimitedPiramal Pharma Limited (PPL, NSE : PPLPHARMA I BSE : 543635) propose une gamme de produits et de services différenciés à partir de ses 17* sites de développement et de fabrication
More news about: Piramal Pharma Solutions
Aug 04, 2026, 18:44 ET Piramal Pharma Solutions amplía sus instalaciones de producción de principios activos peptídicos
receta. Además, una de las empresas asociadas de PPL, Abbvie Therapeutics India Private Limited, una empresa conjunta entre Abbvie y PPL, se ha consolidado como líder del mercado en el área de oftalmología en el sector farmacéutico indio. Asimismo, PPL cuenta con una participación minoritaria estratégica
More news about: Piramal Pharma Solutions
Aug 04, 2026, 05:08 ET Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS),
More news about: Piramal Pharma Solutions
Aug 04, 2026, 04:51 ET Piramal Pharma Solutions Expands Peptide API Facility with Advanced Spray Drying Suite
LimitedPiramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17* global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS),
More news about: Piramal Pharma Solutions
Aug 01, 2026, 03:53 ET 182 Chandigarh University Animation & Multimedia Students Secure Jobs in Top Animation, VFX, Gaming, Digital Media & Filmmaking Studios
https://mmx.prnewswire.com/media/MS1962448/PRESS-PIC-001-ANIMATION-STUDENTS.jpg?id=OA2820606&token=eyJhbGciOiJkaXIiLCJlbmMiOiJBMjU2R0NNIn0..sYcWGCKbWE9AF79I.fzn1GVwO0TRS7dHfZOeQ57gHBkYdR5sUCEnZAR8Isi9SSvPaqSn-d_xnffG6_lC77hD_75EYwyHl6PRtIGNxbd-Qav_sNY6pPlG5Hd1_ZhXy4FJa9humPVMHwrZ3u357-kE._lIE6YY9lfTOM2n0I3tjYg
More news about: Chandigarh University
Jul 30, 2026, 12:33 ET Piramal Pharma Limited annuncia i risultati del primo trimestre dell'anno fiscale 2027
salute. Inoltre, una delle società collegate di PPL, Abbvie Therapeutics India Private Limited, una joint venture tra Abbvie e PPL, è emersa come uno dei leader di mercato nel settore della terapia oftalmologica nel mercato farmaceutico indiano. Inoltre, PPL detiene una partecipazione strategica di minoranza
More news about: Piramal Pharma Limited